During this interactive webinar, a multidiscipline panel of experts will delve into the utility of the cystatin C test in diagnosing kidney disease. They will discuss:
• Epidemiological argument for measuring cystatin C • Benefits of cystatin C related to diagnosis, risk classification, and racial bias • Practical barriers to ordering the cystatin C test • Illustrative case examples
- Silas Norman, MD, MPH University of Michigan
- Josef Coresh, MD, PhD Johns Hopkins University
- Michelle Estrella, MD, MHS University of California - San Francisco
- Amy Karger, MD, PhD University of Minnesota
- Michael Shlipak, MD, MPH University of California - San Francisco
Gentian is a Norwegian diagnostics company that specializes in making novel biomarkers available on the Particle-Enhanced Turbidimetric Immunoassay (PETIA) platform. The company's first commercially available product, The Gentian Cystatin C assay, was launched in 2006 and FDA 510k cleared in 2008. Gentian has since established itself as a global leader in the manufacture of cystatin C assays with its method being one of the few used to evaluate the commutability of the IFCC reference standard. Gentian's current portfolio of diagnostic reagents spans areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine.